April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Safety Evaluation of Novel Drug Delivery Device, the Conjunctival Ring
Author Affiliations & Notes
  • Satoshi Kinoshita
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Kousuke Noda
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Saori Takashina
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Yoko Dong
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Ikuyo Atsumi
    Toxicology Research Laboratory, Senju Pharmaceutical Co., Ltd., Kobe, Japan
  • Haruka Obata
    Research Laboratories, SEED Co., Ltd., Konosu, Japan
  • Toru Matsunaga
    Research Laboratories, SEED Co., Ltd., Konosu, Japan
  • Takeshi Ohguchi
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Atsuhiro Kanda
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Susumu Ishida
    Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • Footnotes
    Commercial Relationships Satoshi Kinoshita, None; Kousuke Noda, None; Saori Takashina, None; Yoko Dong, None; Ikuyo Atsumi, Senju Pharmaceutical Co., Ltd. (E), Senju Pharmaceutical Co., Ltd. (P); Haruka Obata, SEED Co., Ltd. (E), SEED Co., Ltd. (P); Toru Matsunaga, SEED Co., Ltd. (E), SEED Co., Ltd. (P); Takeshi Ohguchi, None; Atsuhiro Kanda, None; Susumu Ishida, Senju Pharmaceutical Co., Ltd. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 482. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Satoshi Kinoshita, Kousuke Noda, Saori Takashina, Yoko Dong, Ikuyo Atsumi, Haruka Obata, Toru Matsunaga, Takeshi Ohguchi, Atsuhiro Kanda, Susumu Ishida; Safety Evaluation of Novel Drug Delivery Device, the Conjunctival Ring. Invest. Ophthalmol. Vis. Sci. 2014;55(13):482.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The conjunctival ring is a novel device designed for drug delivery to the posterior segment of the eye. Previously, we reported that the conjunctival ring efficiently delivers the antibiotics to the retinal and choroidal tissues compared with medicated conventional contact lens (ARVO 2010). In this study, we evaluated the safety of the conjunctival ring containing dexamethasone sodium phosphate (DSP) in mice and rabbits.

Methods: All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Conjunctival rings containing 5% DSP or vehicle (borate buffer) were placed on right and left eyes of C57BL/6J mice, respectively (n=6 eyes each). Twenty-four hours later, corneal fluorescein staining was graded according to the McDonald-Shadduck scoring system, ranging 0 to 4. Similarly, conjunctival rings immersed in 2% DSP, 0.2% DSP, or vehicle solution were placed on the eyes of New Zealand white rabbits for 12 hours per day (n=4 eyes each). As a control, 0.1% dexamethasone metasulfobenzoate sodium was topically administered to the eyes of rabbits 4 times a day (eye-drop group, n=4 eyes). Eight days after, the ocular injury was scored with the McDonald-Shadduck method and lens opacification was assessed with slit-lamp examination. Histologically, infiltration of inflammatory cells in bulbar conjunctiva was evaluated.

Results: In mice, corneal fluorescein staining scores were 2 or less in each eye and no significant difference was observed between the 5% DSP group and vehicle group. In rabbits, the scores were 1 or less in all but 1 eye in the groups. There were no significant differences between the DSP groups and vehicle group. Also, there was no increase of ocular injury in the conjunctival ring groups compared with the eye-drop group, in which all eyes were scored as 0. No remarkable change in crystalline lenses was observed in any group. Histological examination showed a slight infiltration of inflammatory cells in the bulbar conjunctiva in 2 eyes of 0.2% DSP group.

Conclusions: No remarkable side effect of the conjunctival ring was observed in both animal experiments. Our data suggest that the conjunctival ring is a safe device as a drug delivery system.

Keywords: 503 drug toxicity/drug effects • 474 conjunctiva • 487 corticosteroids  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×